Landmark Trial-Based Evidence Supporting the Efficacy, Patient Outcomes, and Safety of PD-1 Checkpoint Inhibition in Advanced and Metastatic CSCC

Landmark Trial-Based Evidence Supporting the Efficacy, Patient Outcomes, and Safety of PD-1 Checkpoint Inhibition in Advanced and Metastatic CSCC

What Do the Trials Teach Us and What Are the Immediate Translational Implications for PD-1 Targeting Immunotherapy in CSCC?


Published

March 25, 2019

Created by

CMEducation Resources symposium

Related Presenters

Chrysalyne Schmults, MD, MSCE

Chrysalyne Schmults, MD, MSCE

Associate Professor of DermatologyHarvard Medical SchoolDirector, Mohs and Dermatologic Surgery Center Brigham and Women’s/Dana Farber Cancer CenterBoston, USA